Organization
University of Colorado Cancer Center, Aurora, CO, USA
4 abstracts
1 poster
Abstract
Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.Org: The Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, Henry Ford Cancer Institute, Detroit, MI, START San Antonio, San Antonio, TX, University of Florida-Health Cancer Center, Orlando Health, Orlando, FL, MUSC Hollings Cancer Center, Charleston, SC,
Abstract
Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial.Org: Winship Cancer Institute of Emory University, Atlanta, GA, University of Alabama at Birmingham, Birmingham, AL, University of California, San Francisco, San Francisco, CA, University of California, San Diego, La Jolla, CA, UC Davis Comprehensive Cancer Center, Sacramento, CA,
Abstract
Streamlining regulatory review in a multicenter platform trial: Opportunity to enhance patient centered care and drive innovation and efficiency.Org: University of California, San Francisco, San Francisco, CA, University of California San Diego Ideker Laboratory, La Jolla, CA, Wake Forest, Winston-Salem, NC, University of California Berkeley, School of Public Health, Berkeley, CA, Alliance for Cancer Clinical Trials, Dana Farber Cancer Institute, I-SPY2, Wrentham, MA,
Abstract
A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced melanoma: Poor-prognosis subgroup analysis.Org: The Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, University of Colorado Cancer Center, Aurora, CO, USA, Henry Ford Cancer Institute, Detroit, MI, Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN, START San Antonio, San Antonio, TX,